Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on December 19, 2024. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities involving Gilead Sciences, Inc.
Key Financial Metrics and Transactions
- Collaboration Payment: The Company will receive an immediate payment of $10.0 million from Gilead.
- Equity Sale: Gilead purchased 940,499 shares of the Company's common stock.
- Share Price: The purchase price was $21.37 per share.
- Premium: The price represented a 35% premium to the lower of the 30-day volume weighted average price immediately prior to the purchase.
- Total Aggregate Payments: The total aggregate payments under the Collaboration Agreement remain unchanged.
Material Changes and Restructuring
The Company and Gilead entered into a First Amendment to their Option, License and Collaboration Agreement. This amendment restructures certain option time points and fees related to the development plan for ABI-6250. The $10.0 million payment received is creditable towards future collaboration-related payments. The opt-in fee for ABI-6250 has been restructured but remains within the range of previously disclosed fees.
Outlook, Risks, and Management Commentary
The restructuring of fees and time points is intended to facilitate the agreed-upon development plan for ABI-6250. The equity sale was conducted pursuant to Section 4(a)(2) of the Securities Act of 1933 as a sale to a single accredited investor. The filing does not provide specific forward-looking guidance, risk factors, or management commentary beyond the description of the transaction mechanics.
Investor Verification Checklist
- Verify the specific terms of the restructured opt-in fee for ABI-6250 in the attached Exhibit 10.1.
- Confirm the impact of the $10.0 million credit on future cash flow projections from the collaboration.
- Review the full text of the First Amendment to understand the revised development timeline.
- Assess the dilution impact of the 940,499 additional shares issued to Gilead.